Eton Pharmaceuticals, Inc.·4

Jun 17, 5:08 PM ET

Adams Jennifer McKie 4

4 · Eton Pharmaceuticals, Inc. · Filed Jun 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Eton (ETON) Director Jennifer Adams Exercises Options, Sells 50,000 Shares

What Happened

  • Jennifer McKie Adams, a director of Eton Pharmaceuticals (ETON), exercised options and sold shares on 2026-06-17. She exercised 50,000 option shares at an exercise price of $3.78 (cost $189,000) and sold 50,000 common shares in the open market for a weighted average price of $32.48, generating gross proceeds of $1,623,795. One form line also reports the disposition of the derivative instrument associated with the options (reported at $0.00), reflecting the conversion/closing out of that derivative position.
  • Net proceeds before taxes and fees are roughly $1.43M (sale proceeds minus exercise cost). This sequence—exercising options and immediately selling the acquired shares—is commonly a cashless exercise and sale; it’s recorded here as an exercise (M) plus an open-market sale (S).

Key Details

  • Transaction date: 2026-06-17 (filed same day).
  • Exercise: 50,000 shares @ $3.78 = $189,000 (code M).
  • Sale: 50,000 shares @ weighted avg $32.48 = $1,623,795 (code S). Individual trade prices ranged $32.10–$32.71 (see footnote).
  • Derivative disposition: 50,000 shares reported as disposed at $0.00 reflecting conversion of the derivative (code M).
  • Shares owned after the transaction: Not specified in the provided filing excerpt.
  • Footnotes: F2 notes the option shares vested quarterly and were fully vested on Feb 7, 2023. F3 clarifies the sale was completed in multiple trades; F1 states per-trade details are available on request.
  • Filing timeliness: Reported with the Form 4 dated the same day as the transactions (appears timely).
  • Remarks: The reporting person authorized a designated filer to submit this Form 4 on their behalf.

Context

  • This is a routine insider transaction pattern: exercising previously granted options (vested in 2023) and selling the acquired shares the same day. Such cashless exercises are typically used to realize gains or cover exercise costs and tax withholding; they do not by themselves indicate the insider’s long-term view.
  • The filing is factual and does not disclose motives, taxes withheld, or transaction-level fees.

Insider Transaction Report

Form 4
Period: 2026-06-17
Transactions
  • Exercise/Conversion

    Common Stock

    2026-06-17$3.78/sh+50,000$189,00050,000 total
  • Sale

    Common Stock

    [F1][F3]
    2026-06-17$32.48/sh50,000$1,623,7950 total
  • Exercise/Conversion

    Employee Stock Option

    [F2]
    2026-06-1750,0000 total
    Exercise: $3.78From: 2023-02-07Exp: 2032-02-06Common Stock (50,000 underlying)
Footnotes (3)
  • [F1]The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F2]The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested on February 7, 2023.
  • [F3]The shares were sold in multiple trades at prices ranging from $32.10 to $32.71. The price reported above reflects the weighted average sales price.
Signature
/s/ Judith Matthews|2026-06-17

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4